Cargando…
High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs
Organotypic culture systems from disease-specific induced pluripotent stem cells (iPSCs) exhibit obvious advantages compared with immortalized cell lines and primary cell cultures, but implementation of iPSC-based high-throughput (HT) assays is still technically challenging. Here, we demonstrate the...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565754/ https://www.ncbi.nlm.nih.gov/pubmed/31080112 http://dx.doi.org/10.1016/j.stemcr.2019.04.014 |
_version_ | 1783426714743865344 |
---|---|
author | Merkert, Sylvia Schubert, Madline Olmer, Ruth Engels, Lena Radetzki, Silke Veltman, Mieke Scholte, Bob J. Zöllner, Janina Pedemonte, Nicoletta Galietta, Luis J.V. von Kries, Jens P. Martin, Ulrich |
author_facet | Merkert, Sylvia Schubert, Madline Olmer, Ruth Engels, Lena Radetzki, Silke Veltman, Mieke Scholte, Bob J. Zöllner, Janina Pedemonte, Nicoletta Galietta, Luis J.V. von Kries, Jens P. Martin, Ulrich |
author_sort | Merkert, Sylvia |
collection | PubMed |
description | Organotypic culture systems from disease-specific induced pluripotent stem cells (iPSCs) exhibit obvious advantages compared with immortalized cell lines and primary cell cultures, but implementation of iPSC-based high-throughput (HT) assays is still technically challenging. Here, we demonstrate the development and conduction of an organotypic HT Cl(−)/I(−) exchange assay using cystic fibrosis (CF) disease-specific iPSCs. The introduction of a halide-sensitive YFP variant enabled automated quantitative measurement of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) function in iPSC-derived intestinal epithelia. CFTR function was partially rescued by treatment with VX-770 and VX-809, and seamless gene correction of the p.Phe508del mutation resulted in full restoration of CFTR function. The identification of a series of validated primary hits that improve the function of p.Phe508del CFTR from a library of ∼42,500 chemical compounds demonstrates that the advantages of complex iPSC-derived culture systems for disease modeling can also be utilized for drug screening in a true HT format. |
format | Online Article Text |
id | pubmed-6565754 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-65657542019-06-20 High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs Merkert, Sylvia Schubert, Madline Olmer, Ruth Engels, Lena Radetzki, Silke Veltman, Mieke Scholte, Bob J. Zöllner, Janina Pedemonte, Nicoletta Galietta, Luis J.V. von Kries, Jens P. Martin, Ulrich Stem Cell Reports Resource Organotypic culture systems from disease-specific induced pluripotent stem cells (iPSCs) exhibit obvious advantages compared with immortalized cell lines and primary cell cultures, but implementation of iPSC-based high-throughput (HT) assays is still technically challenging. Here, we demonstrate the development and conduction of an organotypic HT Cl(−)/I(−) exchange assay using cystic fibrosis (CF) disease-specific iPSCs. The introduction of a halide-sensitive YFP variant enabled automated quantitative measurement of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) function in iPSC-derived intestinal epithelia. CFTR function was partially rescued by treatment with VX-770 and VX-809, and seamless gene correction of the p.Phe508del mutation resulted in full restoration of CFTR function. The identification of a series of validated primary hits that improve the function of p.Phe508del CFTR from a library of ∼42,500 chemical compounds demonstrates that the advantages of complex iPSC-derived culture systems for disease modeling can also be utilized for drug screening in a true HT format. Elsevier 2019-05-09 /pmc/articles/PMC6565754/ /pubmed/31080112 http://dx.doi.org/10.1016/j.stemcr.2019.04.014 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Resource Merkert, Sylvia Schubert, Madline Olmer, Ruth Engels, Lena Radetzki, Silke Veltman, Mieke Scholte, Bob J. Zöllner, Janina Pedemonte, Nicoletta Galietta, Luis J.V. von Kries, Jens P. Martin, Ulrich High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs |
title | High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs |
title_full | High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs |
title_fullStr | High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs |
title_full_unstemmed | High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs |
title_short | High-Throughput Screening for Modulators of CFTR Activity Based on Genetically Engineered Cystic Fibrosis Disease-Specific iPSCs |
title_sort | high-throughput screening for modulators of cftr activity based on genetically engineered cystic fibrosis disease-specific ipscs |
topic | Resource |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6565754/ https://www.ncbi.nlm.nih.gov/pubmed/31080112 http://dx.doi.org/10.1016/j.stemcr.2019.04.014 |
work_keys_str_mv | AT merkertsylvia highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs AT schubertmadline highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs AT olmerruth highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs AT engelslena highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs AT radetzkisilke highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs AT veltmanmieke highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs AT scholtebobj highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs AT zollnerjanina highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs AT pedemontenicoletta highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs AT galiettaluisjv highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs AT vonkriesjensp highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs AT martinulrich highthroughputscreeningformodulatorsofcftractivitybasedongeneticallyengineeredcysticfibrosisdiseasespecificipscs |